Curasight builds its novel uPAR-PET imaging approach on a deep understanding of the uPAR system and it’s role in cancer, together with extensive experience with translational molecular imaging, which has been obtained through more than a decade of research at Rigshospitalet and University of Copenhagen by the scientific team of Professor Andreas Kjaer.

Curasight now introduces new peptide-based PET imaging ligands targeting uPAR.  By non-invasive imaging of uPAR expression, high-volume cancers such as prostate and breast cancer may benefit by improved diagnostic accuracy, risk-stratification and treatment monitoring.  For further explanation on the clinical potential of the technology please click here to see an interview.